Altre lingue Hangzhou Tigermed Consulting Co., Ltd

Azioni

300347

CNE100001KV8

Prezzo di chiusura Shenzhen S.E. Altri mercati azionari 00:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
52,6 ^CNY	-0,92%		-0,30%	-4,31%

23/04	Borse Cina : chiudono miste, male Shanghai -0,7%, bene Hong Kong +1,92%	DJ
29/03	L'utile e il fatturato di Tigermed Consulting salgono nel 2023	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Tigermed Consulting's Profit, Revenue Climb in 2023	29/03
Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024	28/03
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes	21/03
China Healthcare Stocks Rally on Hopes for Government Support	14/03
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	14/03
Hangzhou Tigermed Consulting Plans Up to 1 Billion Yuan Share Repurchase; Shares Jump 4%	07/02
Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 1,000 million worth of its shares.	06/02
Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan.	06/02
Hangzhou Tigermed Consulting's Profit Up 19% in Q3	27/10/23
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Tigermed Reports 2023 Interim Results	28/08/23
Tigermed Consulting's Profit Jumps 16.5% in H1	28/08/23
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
Tigermed Officially Opens International Headquarters in Hong Kong	17/08/23
Bioclub announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd	07/08/23
Hangzhou Tigermed Consulting Co., Ltd. Announces Final Profit Distribution Plan Implementation (A Shares) for 2022, Payable on 07 July 2023	04/07/23
Hangzhou Tigermed Consulting Co. Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2022, Payable on 07 July 2023	26/06/23
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.	20/06/23
Hangzhou Tigermed Consulting Names Chairman, Other Officials	24/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Hangzhou Tigermed Consulting Co., Ltd

Azioni

300347

CNE100001KV8

Altre lingue

Filtri